CDK4 and melanoma: Single-arm studies evidenced clinical activity of CDK4/6 inhibitors in a subset of patients suffering from mantle cell lymphoma, liposarcoma, melanoma, non-small cell lung cancer, glioblastoma, neuroblastoma and malignant rhabdoid tumors [73,91,92,93].